The recommendations — issued earlier this year — incorporate research published since the society released its initial guidelines in “With this most recent update, ASCO has offered a much more structured guideline. There is an order of preference for treatment and it is a useful tool for clinicians,” . . . Read more . . .
ASCO released updated recommendations that incorporate new evidence related to second-line therapy for patients with metastatic pancreatic cancer who progressed on or experienced intolerable toxicity during first-line therapy.